Brief: Knight Therapeutics And Sumitomo Pharma Enter Into Exclusive Licensing Agreements To Commercialize Sumitomo’S Canadian Portfolio
05/06/2025 12:16
Knight Therapeutics Inc GUD.TO: KNIGHT THERAPEUTICS AND SUMITOMO PHARMA ENTER INTO EXCLUSIVE LICENSING AGREEMENTS TO COMMERCIALIZE SUMITOMO’S CANADIAN PORTFOLIO KNIGHT THERAPEUTICS INC - DEAL INCLUDES UPFRONT AMOUNT OF C$25.4 MILLION KNIGHT THERAPEUTICS: MAY PAY FUTURE CONTINGENT PAYMENTS OF UP TO C$15.75 MILLION KNIGHT THERAPEUTICS INC - EXPECTED TO PAY C$7 MILLION FOR INVENTORY Source text: ID:nGNXbyJZJq Further company coverage: GUD.TO
Recent news on Knight Therapeutics
See all newsBrief: Knight Therapeutics Announces Regulatory Approval Of Niktimvo In Brazil
Brief: Knight Therapeutics - Launches Tavalisse In Brazil For Chronic Immune Thrombocytopenia
Brief: Knight Therapeutics Enters Into Exclusive Distribution Agreement With Kyowa Kirin International For Poteligeo® (Mogamulizumab)
Brief: Knight Therapeutics Announces Regulatory Approval Of Tavalisse® In Colombia
Brief: Knight Therapeutics Announces Supplemental Regulatory Submission For Minjuvi In Brazil